Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N7N8 | ISIN: KYG4818G1010 | Ticker-Symbol: 6IB
Tradegate
20.12.24
18:25 Uhr
4,300 Euro
-0,120
-2,71 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
INNOVENT BIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
INNOVENT BIOLOGICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,3204,42021.12.
4,3004,58020.12.

Aktuelle News zur INNOVENT BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrINNOVENT BIO (01801): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES ROS1 INHIBITOR DOVBLERON (TALETRECTINIB ADIPATE CAPSULE)-
FrBofAS Cuts CSPC PHARMA's TP to $4.6, Lifts INNOVENT BIO's TP to $56.4 2
INNOVENT BIOLOGICS Aktie jetzt für 0€ handeln
MoInnovent and Lilly Partner to Bring Innovative Cancer Treatment to China16
MoInnovent gains China rights to Lilly's cancer drug Jaypirca4
MoInnovent Biologics: Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (pirtobrutinib) in Mainland China53SAN FRANCISCO and SUZHOU, China, Dec. 15, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
09.12.Innovent Biologics: Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 202464SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
05.12.INNOVENT BIO (01801): GRANT OF SHARE OPTIONS AND RESTRICTED SHARES3
03.12.HUTCHMED (China) Limited: HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE (Fruquintinib) in Combination with TYVYT (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer77- First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China)...
► Artikel lesen
03.12.INNOVENT BIO (01801): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED CONDITIONAL APPROVAL FOR TYVYT (SINTILIMAB INJECTION) ...1
03.12.Hutchmed China Ltd - HUTCHMED and Innovent Announce ELUNATE Approval-
28.11.INNOVENT BIO (01801): VOLUNTARY ANNOUNCEMENT - FIRST-TIME INCLUSION OF SINTBILO (TAFOLECIMAB INJECTION) AND NEW INDICATION FOR OLVEREMBATINIB IN CHINA'S ...1
07.11.Innovent ditches low-value stake sale after investor outcry3
04.11.Innovent Rallies as Chinese Pharma Firm Pulls Out of Equity Sale in Overseas Arm to Founder6
30.10.INNOVENT BIO (01801): INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE THIRD QUARTER OF 20246
29.10.Innovent, awaiting Chinese regulators' verdict, posts another psoriasis win for IL-23 drug5
29.10.Innovent Biologics: Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics79SAN FRANCISCO and SUZHOU, China, Oct. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
25.10.INNOVENT BIO (01801): CONNECTED TRANSACTION - PROPOSED SUBSCRIPTION AND DEEMED DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY6
17.10.Innovent Biologics: Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint96SAN FRANCISCO and SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
► Artikel lesen
08.10.Innovent and ASK Pharm to commercialise limertinib for lung cancer2
08.10.Innovent Biologics: Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer65SAN FRANCISCO and SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
► Artikel lesen
Seite:  Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1